Clinical Trials Logo
  1. Home
  2. Myeloproliferative Disorder
  3. NCT03688490
  4. Details
NCT03688490 Clinical Trial

Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms

Myeloproliferative Disorder Clinical Trial

— PASYMPLE  

Official title:
Aquagenic Pruritus Among Patients With Myeloproliferative Syndromes (in English) Prurit Aquagénique Dans Les SYndromes MyéloProLifEratifs (in French)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03688490
Other study ID # PASYMPLE
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 17, 2013
Est. completion date November 4, 2013

Study information
Verified date August 2018
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Description:

Patients with myeloproliferative neoplasms identified and followed in our Institution (Brest University Hospital). Patients could be followed for polycythemia vera or essential thrombocythemia or myelofibrosis.

Distribution of the questionnaire to each patients with myeloproliferative neoplasms (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Recruitment information / eligibility
Status Completed
Enrollment 70
Est. completion date November 4, 2013
Est. primary completion date November 4, 2013
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- patients followed with myeloproliferative neoplasms

- suffering from aquagenic pruritus

Exclusion Criteria:

- Unable to fulfil the questionnaire

- No written informed consent

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Brest

References & Publications (1)

Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol. 2017 Jan;176(1):255-258 — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Intensity of the pruritus Analogic Visual Scale, from 0 to 10, Worse if >6 15 days
Secondary Duration of the pruritus Timing expresses in minutes 15 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06246006 - Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia
Completed NCT03907436 - The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase N/A
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Completed NCT03149055 - Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) Phase 2
Completed NCT01866839 - Preventing Stem Cell Transplant Complications With a Blood Separator Machine Phase 1/Phase 2
Recruiting NCT05884333 - Cord Blood Transplant in Adults With Blood Cancers Phase 2
Completed NCT00588666 - Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Phase 2
Active, not recruiting NCT03480360 - Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Phase 3
Completed NCT00539695 - Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Phase 2
Recruiting NCT03869476 - Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. N/A
Completed NCT00175838 - Primary Thrombocythaemia 1 Trial N/A
Active, not recruiting NCT03434730 - Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Phase 2
Recruiting NCT03852407 - Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning Phase 2
Completed NCT01499147 - Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies N/A
Completed NCT00533923 - Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Phase 2
Active, not recruiting NCT04473911 - Haplo Peripheral Blood Sct In GVHD Prevention Phase 1
Completed NCT00909467 - Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases N/A
Completed NCT00687414 - Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders
Recruiting NCT03808805 - Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms Phase 3